World-First Rapid Test for Early Dementia Risk

AD Check認知測™ Rapid utilizes world-leading patented technology to detect Amyloid β-protein fragments in urine—a key biomarker associated with dementia—to assist in screening potential cognitive risks. Designed as a rapid diagnostic kit, the test requires only a small urine sample and delivers results with 10 minutes. This non-invasive, streamlined, and highly efficient workflow makes it an ideal tool for both preliminary screenings and long-term health monitoring. By identifying risk signals early, users can strategically plan targeted medical follow-ups and professional diagnostics, ensuring critical intervention during the " golden intervention period."

The technology has earned extensive international recognition, including the CE certification (EU) and medical device registrations across China and Southeast Asia. It holds invention patents in major jurisdictions, including China, Europe, Japan, and Australia. Clinical studies comparing AD Check™ Rapid with Aβ-PET imaging demonstrate high diagnostic performance, with sensitivity and specificity reaching approximately 80% and 90%, respectively